HIV-vaccine research and development in Thailand: evolution and challenges
Punnee Pitisuttithum1, Kachit Choopanya, Supachai Rerk-Ngnam
1Faculty of Tropical Medicine, Mahidol University 420/6 Ratchawithi Road, Ratchathewi, Bangkok 10400, Thailand. tmppt@mahidol.ac.th
Abstract:
Thailand has been committed to HIV-Vaccine Research and Development since the launch of its National Plan, in 1993. Series of phase I/II trials, and two phase III clinical trials, have been conducted. The first efficacy trial was conducted with a high-risk group, injecting drug users (IDUs), and the second involved communities in the Eastern-seaboard provinces of Thailand. Both involved similar challenges in terms of infrastructure strengthening, capacity building, implementing the trials into the existing health system, staffing, and commitments. However, there were different issues in recruitment process, follow up, social impact events and community involvement since the target participants were different.
More Related Videos
10:58Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
Published on: August 21, 2019
14:23A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses
Published on: August 31, 2014
Related Concept Videos
Vaccine Production
Viral Mutations
Microorganisms in Medicine and Therapeutics
Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Preclinical Development: Overview
Clinical Trials: Overview
